Skip to main content
Erschienen in: Current Hepatology Reports 4/2018

17.10.2018 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma

verfasst von: Ju Dong Yang, Lewis R. Roberts

Erschienen in: Current Hepatology Reports | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To review the recent consensus on the nomenclature, clinical features, diagnosis, and treatment of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA).

Recent Findings

cHCC-CCA is a primary liver carcinoma with varying degrees of hepatocytic and cholangiocytic cytology and architecture within the same tumor. The diagnosis of cHCC-CCA can only be established based on histologic examination. Surgical resection should be considered in patients with resectable tumors who do not have underlying liver disease or clinically significant portal hypertension. While treatment by liver transplantation (LT) is controversial due to the high risk of post-LT recurrence, LT should remain as a potentially curative option in a highly selected group of patients. Little data exist for the outcome of other treatments.

Summary

High-quality multicenter prospective studies should be conducted to better understand this rare but increasingly recognized tumor.
Literatur
1.
Zurück zum Zitat •• Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68(1):113–26. Consensus article of combined hepatocellular carcinoma-cholangiocarcinoma from an international community of pathologists, radiologists, and clinicians. •• Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology. 2018;68(1):113–26. Consensus article of combined hepatocellular carcinoma-cholangiocarcinoma from an international community of pathologists, radiologists, and clinicians.
2.
Zurück zum Zitat Chen J, He J, Deng M, Wu HY, Shi J, Mao L, et al. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. Hum Pathol. 2017;64:118–27.CrossRef Chen J, He J, Deng M, Wu HY, Shi J, Mao L, et al. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. Hum Pathol. 2017;64:118–27.CrossRef
3.
Zurück zum Zitat Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017;66(5):952–61.CrossRef Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, et al. Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol. 2017;66(5):952–61.CrossRef
4.
Zurück zum Zitat • Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology. 2017;70(3):423–34 Article that describes the mutational spectrum of combined hepatocellular carcinoma-cholangiocarcinoma and the association between mutations and underlying etiology, clinicopathologic features of tumor.CrossRef • Sasaki M, Sato Y, Nakanuma Y. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology. 2017;70(3):423–34 Article that describes the mutational spectrum of combined hepatocellular carcinoma-cholangiocarcinoma and the association between mutations and underlying etiology, clinicopathologic features of tumor.CrossRef
5.
Zurück zum Zitat Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am. 2017;46(2):365–91.CrossRef Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am. 2017;46(2):365–91.CrossRef
6.
Zurück zum Zitat Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl. 2014;20(8):952–9.CrossRef Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl. 2014;20(8):952–9.CrossRef
7.
Zurück zum Zitat Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M. Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor. Ann Surg Oncol. 2012;19(5):1628–36.CrossRef Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M. Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor. Ann Surg Oncol. 2012;19(5):1628–36.CrossRef
8.
Zurück zum Zitat Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, Franco D, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol. 2004;41(2):292–8.CrossRef Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, Franco D, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol. 2004;41(2):292–8.CrossRef
9.
Zurück zum Zitat Li R, Yang D, Tang CL, Cai P, Ma KS, Ding SY, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer. 2016;16:158.CrossRef Li R, Yang D, Tang CL, Cai P, Ma KS, Ding SY, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer. 2016;16:158.CrossRef
10.
Zurück zum Zitat • Bergquist JR, Groeschl RT, Ivanics T, Shubert CR, Habermann EB, Kendrick ML, et al. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB. 2016;18(11):886–92 The largest study that compares the clincial features and outcomes of patients with combined hepatocellular carcinoma-cholangiocarcinoma vs. hepatocellular carcinoma and cholangiocarcinoma. CrossRef • Bergquist JR, Groeschl RT, Ivanics T, Shubert CR, Habermann EB, Kendrick ML, et al. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB. 2016;18(11):886–92 The largest study that compares the clincial features and outcomes of patients with combined hepatocellular carcinoma-cholangiocarcinoma vs. hepatocellular carcinoma and cholangiocarcinoma. CrossRef
11.
Zurück zum Zitat Yoon YI, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastroint Surg. 2016;20(2):411–20.CrossRef Yoon YI, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastroint Surg. 2016;20(2):411–20.CrossRef
12.
Zurück zum Zitat Zhan Q, Shen BY, Deng XX, Zhu ZC, Chen H, Peng CH, et al. Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center. J Hepatobiliary Pancreat Sci. 2012;19(4):361–9.CrossRef Zhan Q, Shen BY, Deng XX, Zhu ZC, Chen H, Peng CH, et al. Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center. J Hepatobiliary Pancreat Sci. 2012;19(4):361–9.CrossRef
13.
Zurück zum Zitat Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189(1):120–5.CrossRef Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189(1):120–5.CrossRef
14.
Zurück zum Zitat Semelka RC, Nimojan N, Chandana S, Ramalho M, Palmer SL, DeMulder D, et al. MRI features of primary rare malignancies of the liver: a report from four university centres. Eur Radiol. 2018;28(4):1529–39.CrossRef Semelka RC, Nimojan N, Chandana S, Ramalho M, Palmer SL, DeMulder D, et al. MRI features of primary rare malignancies of the liver: a report from four university centres. Eur Radiol. 2018;28(4):1529–39.CrossRef
15.
Zurück zum Zitat Dong Y, Teufel A, Trojan J, Berzigotti A, Cui XW, Dietrich CF. Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: case series and review of the literature. Digest Liver Dis. 2018;50(4):401–7.CrossRef Dong Y, Teufel A, Trojan J, Berzigotti A, Cui XW, Dietrich CF. Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: case series and review of the literature. Digest Liver Dis. 2018;50(4):401–7.CrossRef
16.
Zurück zum Zitat • Wells ML, Venkatesh SK, Chandan VS, Fidler JL, Fletcher JG, Johnson GB, et al. Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging. 2015;40(7):2293–305 Comprehensive description of CT, MRI, PET/CT, and ultrasound findings in combined hepatocellular carcinoma-cholangiocarcinoma. CrossRef • Wells ML, Venkatesh SK, Chandan VS, Fidler JL, Fletcher JG, Johnson GB, et al. Biphenotypic hepatic tumors: imaging findings and review of literature. Abdom Imaging. 2015;40(7):2293–305 Comprehensive description of CT, MRI, PET/CT, and ultrasound findings in combined hepatocellular carcinoma-cholangiocarcinoma. CrossRef
17.
Zurück zum Zitat Fowler KJ, Sheybani A, Parker RA 3rd, Doherty S, Brunt ME, Chapman WC, et al. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol. 2013;201(2):332–9.CrossRef Fowler KJ, Sheybani A, Parker RA 3rd, Doherty S, Brunt ME, Chapman WC, et al. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol. 2013;201(2):332–9.CrossRef
18.
Zurück zum Zitat Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013;37(4):496–505.CrossRef Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013;37(4):496–505.CrossRef
19.
Zurück zum Zitat Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16(3):623–9.CrossRef Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16(3):623–9.CrossRef
20.
Zurück zum Zitat Groeschl RT, Turaga KK, Gamblin TC. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol. 2013;107(6):608–12.CrossRef Groeschl RT, Turaga KK, Gamblin TC. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol. 2013;107(6):608–12.CrossRef
21.
Zurück zum Zitat Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94(7):2040–6.CrossRef Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94(7):2040–6.CrossRef
22.
Zurück zum Zitat Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33(6):283–7.CrossRef Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33(6):283–7.CrossRef
23.
Zurück zum Zitat Vilchez V, Shah MB, Daily MF, Pena L, Tzeng CW, Davenport D, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB. 2016;18(1):29–34.CrossRef Vilchez V, Shah MB, Daily MF, Pena L, Tzeng CW, Davenport D, et al. Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB. 2016;18(1):29–34.CrossRef
24.
Zurück zum Zitat Park YH, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. Transplant Proc. 2013;45(8):3038–40.CrossRef Park YH, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. Transplant Proc. 2013;45(8):3038–40.CrossRef
25.
Zurück zum Zitat Lunsford KE, Court C, Lee YS, Lu DS, Naini BV, Harlander-Locke MP, et al. Propensity matched analysis of patients with mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2018. https://doi.org/10.1002/lt.25058. Lunsford KE, Court C, Lee YS, Lu DS, Naini BV, Harlander-Locke MP, et al. Propensity matched analysis of patients with mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing liver transplantation. Liver Transpl. 2018. https://​doi.​org/​10.​1002/​lt.​25058.
26.
Zurück zum Zitat Elshamy M, Presser N, Hammad AY, Firl DJ, Coppa C, Fung J, et al. Liver transplantation in patients with incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience. Hepatobiliary Pancreat Dis Int. 2017;16(3):264–70.CrossRef Elshamy M, Presser N, Hammad AY, Firl DJ, Coppa C, Fung J, et al. Liver transplantation in patients with incidental hepatocellular carcinoma/cholangiocarcinoma and intrahepatic cholangiocarcinoma: a single-center experience. Hepatobiliary Pancreat Dis Int. 2017;16(3):264–70.CrossRef
27.
Zurück zum Zitat Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(5):1263–7.CrossRef Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(5):1263–7.CrossRef
28.
Zurück zum Zitat • Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology (Baltimore, Md). 2016;64(4):1178–88 Article that supports using liver transplant for the management of combined hepatocellular carcinoma-cholangiocarcinoma. CrossRef • Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology (Baltimore, Md). 2016;64(4):1178–88 Article that supports using liver transplant for the management of combined hepatocellular carcinoma-cholangiocarcinoma. CrossRef
29.
Zurück zum Zitat Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66.CrossRef Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66.CrossRef
30.
Zurück zum Zitat Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9(7):617–23.e1.CrossRef Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol. 2011;9(7):617–23.e1.CrossRef
31.
Zurück zum Zitat Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology. 2010;255(1):270–7.CrossRef Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology. 2010;255(1):270–7.CrossRef
32.
Zurück zum Zitat Chan LS, Sze DY, Poultsides GA, Louie JD, Abdelrazek Mohammed MA, Wang DS. Yttrium-90 radioembolization for unresectable combined hepatocellular-cholangiocarcinoma. Cardiovasc Intervent Radiol. 2017;40(9):1383–91.CrossRef Chan LS, Sze DY, Poultsides GA, Louie JD, Abdelrazek Mohammed MA, Wang DS. Yttrium-90 radioembolization for unresectable combined hepatocellular-cholangiocarcinoma. Cardiovasc Intervent Radiol. 2017;40(9):1383–91.CrossRef
33.
Zurück zum Zitat Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer. 2018;118(3):325–30.CrossRef Salimon M, Prieux-Klotz C, Tougeron D, Hautefeuille V, Caulet M, Gournay J, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer. 2018;118(3):325–30.CrossRef
34.
Zurück zum Zitat Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastroint Oncol. 2017;8(2):347–51.CrossRef Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastroint Oncol. 2017;8(2):347–51.CrossRef
35.
Zurück zum Zitat Kohler BC, Waldburger N, Schlamp K, Jager D, Weiss KH, Schulze-Bergkamen H, et al. Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. Oncotarget. 2017;8(35):59991–8.CrossRef Kohler BC, Waldburger N, Schlamp K, Jager D, Weiss KH, Schulze-Bergkamen H, et al. Liver cancers with stem/progenitor-cell features - a rare chemotherapy-sensitive malignancy. Oncotarget. 2017;8(35):59991–8.CrossRef
36.
Zurück zum Zitat Zhou A, Amin M, Fowler KJ, Brunt EM, Keller J, Tan B. Complete response to Erlotinib and bevacizumab in a patient with biphenotypic (hepatobiliary) primary liver carcinoma. J Natl Compr Cancer Netw. 2015;13(12):1468–73.CrossRef Zhou A, Amin M, Fowler KJ, Brunt EM, Keller J, Tan B. Complete response to Erlotinib and bevacizumab in a patient with biphenotypic (hepatobiliary) primary liver carcinoma. J Natl Compr Cancer Netw. 2015;13(12):1468–73.CrossRef
37.
Zurück zum Zitat El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England). 2017;389(10088):2492–502.CrossRef El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England). 2017;389(10088):2492–502.CrossRef
38.
Zurück zum Zitat Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017;357(6349):409–13.CrossRef Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, NY). 2017;357(6349):409–13.CrossRef
39.
Zurück zum Zitat Bang YJ, Doi T, Braud FD, Piha-Paul S, Hollebecque A, Razak ARA, et al. 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028. Eur J Cancer. 2015;51:S112.CrossRef Bang YJ, Doi T, Braud FD, Piha-Paul S, Hollebecque A, Razak ARA, et al. 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028. Eur J Cancer. 2015;51:S112.CrossRef
40.
Zurück zum Zitat Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111.CrossRef Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111.CrossRef
Metadaten
Titel
Management of Combined Hepatocellular Carcinoma-Cholangiocarcinoma
verfasst von
Ju Dong Yang
Lewis R. Roberts
Publikationsdatum
17.10.2018
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 4/2018
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-018-0431-9

Weitere Artikel der Ausgabe 4/2018

Current Hepatology Reports 4/2018 Zur Ausgabe

Fatty Liver Disease (Z Younossi, Section Editor)

Surgical Issues in NASH: Bariatric Surgery and Liver Transplantation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.